Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Pharma is pouring billions into AI. The biggest returns may take years to prove.

By Brian Buntz | November 16, 2026

Clipboard, woman and scientist writing in laboratory for medical research on cancer drug trial. Checklist, investigation and female biologist with clinic protocol development for pharmaceutical study.

[Adobe Stock]

Within the AI industry, a growing number of insiders see early signs of recursive self-improvement. In other words, models are getting better at helping train their successors. While humans are still involved, automation is gaining ground in frontier AI labs’ processes ranging from curating data to tuning hyperparameters and training code. Headline deal sizes for AI drug discovery among the top 20 pharma companies doubled to $29.5 billion in 2025, according to McKinsey. Only $600 million of that, about 2%, was paid up front, with 60% to 90% of contract value tied to clinical and commercial milestones. Of 38 deals signed in 2023 and 2024, less than 1% of maximum milestone value had been paid out by June 2026.

Pharma is investing aggressively in AI to make processes ranging from early stage discovery to clinical trials more efficient. The former area in particular is growing briskly. Venture and private equity funding for AI-enabled drug discovery roughly doubled from $4.1 billion in 2023 to $8.4 billion in 2025, according to McKinsey. Meanwhile, the cost of developing a drug keeps rising. The average cost from discovery to launch rose to $2.67 billion in 2025 from $2.23 billion in 2024, according to Deloitte. For context, the average cost was about $2 billion in 2021.

Among selected AI-enabled programs with enough self-reported and public data, first-in-human or equivalent preclinical milestones arrived 15% to 80% faster than large-pharma medians, according to McKinsey’s September report.

But while agentic loops are steadily improving in software development and AI development, similar loops are far harder to engineer and close in pharma. Mind-boggling complexity runs through every layer, spanning the biology, organizational culture and the clinical trials and post-market signals that follow a drug to patients. If it gets that far.

Guang Yang

Guang Yang, McKinsey

Drug discovery, of course, spans a spectrum of distinct problems, each with its own data and its own best-fit model, and a single program can require a molecule that clears several of them at once. “Developing a successful drug candidate requires balancing many different properties, from potency and selectivity to safety and how the molecule behaves in the body,” said Guang Yang, a partner at McKinsey. “Different computational models can help predict and optimize these properties, but the real challenge is finding a molecule that meets the necessary criteria at the same time.”

He described a recent conversation with a biotech company seeking a small molecule that could modulate a specific ion channel, achieve greater selectivity than existing compounds, penetrate the brain, and demonstrate a suitable pharmacokinetic and pharmacodynamic profile.

“They’re essentially looking for a unicorn, a molecule that sits at the intersection of many demanding requirements,” he said. “Optimizing any one property can be done, but achieving the right combination is much harder. That’s one of the fundamental challenges in drug discovery.”

In the lab: Building AI traction meets biological complexity

AI investment has clustered in molecule design because the experiments report back quickly. A model proposes an antibody, scientists make it and within weeks an assay shows whether it binds. Yang contrasts that cycle to a math problem, where a wrong answer shows up immediately and the model can be corrected. “If you go through 1,000 iterations of feedback, the model will unquestionably improve,” he said. The same kind of fast, unambiguous feedback is available in formal theorem proving and competition math, where a proof assistant or answer key catches a wrong step immediately, and in software engineering, where unit tests or a compiler return a pass/fail signal within seconds.

In drug discovery, a given binding result is only one answer among many. The molecule in the aforementioned example also has to be specific for its target, reach the brain, and behave well in the body overall. A tool that helps with one of these properties can leave the others unresolved. Establishing whether a drug ultimately helps patients requires a much longer chain of evidence.

Christian Baber

Christian Baber, Pistoia Alliance

Even where scientists can test predictions, they have to trust the tools. Chat interfaces have raised expectations that AI should just work, said Christian Baber, chief portfolio officer at the Pistoia Alliance, a life sciences collaboration organization. Scientific applications demand consistency, and the controls that enforce it can make systems harder to use.

Speaking of LLMs’ potential to, at times, be confidently wrong, Baber said that distrust in them has been an issue among chemists, for instance. “It’s quite difficult to build trust and really easy to lose it,” he said of LLMs. While models’ performance steadily improves with new models, they remain probabilistic. And a confident error backed by an invented reference can end a scientist’s willingness to use a system. Pistoia’s surveys have found AI’s value in document drafting and summarizing, where users expect to check the output. Having AI draft clinical protocols and certain reports can save “weeks or months of people’s time,” Baber said, and the drafts still need checking, as a human’s would.

One workaround is to have the model build deterministic workflows. In the Alliance’s work on instrument data converters, researchers ask an LLM to write a Python script for converting data, then test, validate and reuse the script. “You use something unpredictable to generate something predictable, and that’s what you use,” Baber said. Regulators are more receptive to that approach, he added.

Shared data is another example of a common bench-level problem. Some labs still share reports while keeping the underlying data within their group. Some have a FAIR data system and still keep the data inside the lab, he said. AI’s demand for accessible data is pushing companies toward central storage, with reports generated from that shared resource. Baber also wants researchers to capture why they ran an experiment, what they expected and what they concluded, so the next scientist can understand the question behind a measurement. Getting that context into a shared system requires people to change their daily work. Some companies now count only what reaches the electronic lab notebook, and Baber sketched how that conversation goes: “I did 30 syntheses last month.” “Your ELN says you didn’t do any.” “Oh, I just didn’t put them in my ELN.” “Well, then you didn’t do them.” What’s still missing, he said, “is the carrot for people.”

Culture change is tricky from the lab up to the executive ranks

As has long been the case for digital and process changes in R&D, the people are the bottleneck. “The issue with digital transformation is not the technology; it’s the people. They’re too busy,” Baber said. Scientists have experiments to finish while their employers introduce new software, data requirements and ways of working. Baber traced the Alliance’s change-management community, formed about a year to 18 months ago, to an idea from Novo and that recurring complaint.

One common response has been to borrow agile methods from software development, short cycles of iteration and continuous adjustment. “Agile is great in theory. In practice, it means never-ending change for the people in the lab who are trying to get work done,” he said.

The Alliance’s January white paper, Elevating Organizational Change Management in Pharma and Life Sciences, draws on five structured sessions and survey data from seven pharmaceutical companies and two technology partners. Participants described “change theater”: elaborate communications, meetings and rollout plans that leave users’ needs unresolved. Most respondents rated several practices as unmet, including preparing users before rollout, assigning clear accountability, updating operational documents and securing advocacy from project or department leaders.

The problem of change management extends throughout organizations, including to the executive ranks. Some leaders “will quite often talk the talk but not walk the walk,” Baber said, asking employees to help design and adopt a technology without lightening their workload. “You’re punishing people for implementing and adopting these new technologies, because you’re giving them extra work and no extra time to do it in,” Baber said. A trained chemist, he compares digital transformation to a reaction that needs energy up front before it settles at a lower state. “There’s work at first, but in the end it takes less work to get the same amount done. Quite often it doesn’t work like that,” he said. His alternative to carrot and stick is time: “allowing time to do what is necessary.”

The Pistoia Alliance recommends involving users early, rewarding feedback and peer mentoring, and pairing central change-management standards with practitioners embedded in project teams. In practice, that means time for adoption, someone responsible for helping users, and a route for their feedback to change the implementation.

Incentives need a similar type of grounding. Counting ideas or candidates handed to the next team encourages employees to optimize for volume. Baber argues that rewards should reflect developability, clinical endpoints and translation, even though those outcomes take longer to assess. “If your carrot is how many things are thrown over the fence, all you’ll do is barely clear the fence and not get the best candidate,” he said.

Yang sees companies pursuing two parallel tracks. The first is decentralized experimentation, giving individual researchers the freedom to adopt tools best suited to their work. “You have 16,000 individual employees, and they all need to experiment with whatever tool is out there, and that may change every three months,” Yang said.

The second track involves institution-wide big bets on problems that require coordinated teams, substantial infrastructure or strategic partnerships. Unlike individual experimentation, these investments demand executive conviction years before results become visible.

Pharmaceutical companies are taking different approaches. Some are investing heavily ahead of proven returns, including building or scaling supercomputing modeling capabilities. Others are holding back, risking a late start in developing critical capabilities if the technology delivers on its promise around 2030. A third group is pursuing partnerships that tie payments to development milestones, shifting much of the early financial risk to partners and their investors. Headline deal value among the top 20 pharma companies doubled to $29.5 billion in 2025, but up-front cash came to $0.6 billion, or 2%, and partners in 38 deals signed in 2023 and 2024 had collected less than 1% of maximum milestone value by June 2026, the McKinsey report says.

“R&D is always about this: whatever you invest in now will only materialize in seven years. It requires people to have conviction before they actually have the data,” he said.

Waiting months or even years

Feedback slows dramatically once a candidate reaches people. Whether a molecule binds to a target can often be tested within weeks. Whether a drug is safe and effective in humans may take years to establish. That difference matters for AI, which improves by learning from experimental results. “Imagine every time you tell the model it’s wrong, you have to wait five years, versus just a month,” Yang said.

Earlier prediction of human toxicity is one of the biggest prizes. Roughly one-quarter of Phase 2 and Phase 3 failures stem from unpredicted safety issues, according to McKinsey’s report, and animal livers differ enough from human ones that a drug can pass preclinical tests and still fail. “Better predictions could help companies identify problematic candidates earlier, but whether AI can meaningfully improve overall clinical success rates remains an open question,” Yang said.

Where the training data comes from

Pooling clinical readouts requires waiting for enough trials to generate meaningful evidence. Efforts to aggregate the data used to train AI models, meanwhile, have been underway for years. “One school of thought is that AI performance depends heavily on the quality and scale of training data, so companies with access to the richest datasets will have an advantage,” said Guang Yang, a partner at McKinsey. The challenge is that much of the industry’s most valuable proprietary data remains fragmented within individual pharmaceutical companies, limiting opportunities to learn from the collective experience of drug development.

Central storage, the shift Baber describes, handles that inside one company. Federated learning works across companies: the model trains on each participant’s data where it sits, and only what it learned comes back, so each company keeps its molecules and targets in house. Ten drugmakers, among them AstraZeneca, GSK, Novartis and Bayer, tested the approach in MELLODDY, a project funded in part by Europe’s Innovative Medicines Initiative. Each improved its own predictive models, with the largest gains in pharmacokinetics and safety-panel assays, the consortium reported in the Journal of Chemical Information and Modeling.

Consortiums such as MELLODDY took a large dataset to join, which left smaller companies out, said Aliza Apple, who proposed Lilly’s TuneLab and leads it. Lilly’s pitch to them, in her words: “If you participate, and we all stop living inside our own little black boxes, we can all gain here.” TuneLab, which also uses federated learning, gives members Lilly’s models on day one and a year to contribute data from molecules and assays they choose. It passed 150 member companies this week. Their roughly 675,000 data points have added 30% to the training data, Apple said. The gain Lilly tracks is reach more than accuracy, she said: partner data has expanded the models’ chemical-space coverage by a double-digit percentage, extending predictions to molecules unlike Lilly’s own.

Lilly also steers members toward preferred protocols at five contract research organizations, among them Charles River and Twist Bioscience. Labs often measure the same property with different assays, which the models learn as separate tasks, Apple said. Fewer protocols let small contributions pool.

For a biotech startup, the wait for feedback can determine whether the company survives. A failed lead program can cut off funding before it gets another chance. “If you’re looking at just one drug candidate, statistically, it’s much more likely to fail than succeed,” Yang said. “Historically, roughly 90% of assets entering Phase 1 never make it to approval.” The industry’s learning curve can outlast the companies generating the evidence.

“The inherent problem is you need to pool multiple trials to get a statistically robust number,” Yang said. The industry has encountered similar challenges before. Evidence accumulated across many development programs has helped establish that drugs targeting well-validated causal human biology tend to have higher success rates. For AI-originated drugs, McKinsey doesn’t expect that critical mass of readouts until around 2030; most AI-native clinical assets remain in Phase 1 or Phase 2, and definitive Phase 3 efficacy readouts are years away, the report says. Until then, each readout is a one-off. “It’s like a weather forecast predicting a 60% chance of rain. If it doesn’t rain that day, it doesn’t mean the forecast was wrong,” he said. “You need to look at hundreds of forecasts to know whether the predictions are accurate.”

Trial operations offer a faster loop inside the slow one. Operational data is well structured, Yang said, and enrollment shows within about a month whether a team picked the right sites, so AI can learn while a study runs toward its clinical endpoints. “Right now, Phase 1 to approval takes roughly seven years. Imagine squeezing that down to four. That’s going to be worth billions and billions,” he said.

For now, the push to reduce experimentation through AI may actually be increasing it. Companies are investing in large-scale biological data generation to train and improve their models, creating additional demand for laboratory experiments, consumables and equipment. Yang calls it a “training bump.” “Of course, the question is how long the training bump will last,” he said. “When will AI be good enough that the balance tips over?”

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

As AI bubble talk grows, Dwarkesh Patel predicts recursive self-improvement will set off an AI research explosion
Elsevier survey: 63% of corporate R&D staff say a key decision rested on flawed data
A two-armed white robot with dexterous hands above a lab bench holding a glass funnel on a ring stand, a beaker and a wash bottle
NVIDIA’s GR00T 2 reaches 95% on selected robot tasks after five demonstrations
Female doctor using medical AI assistant on laptop computer in clinic office. modern medicine
Google is teaching healthcare professionals to incorporate AI into the everyday practice of medicine
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.

R&D World Digital Issues

Fall 2026 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE